导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.81% | 1990/4773 |
| 近一周 | -0.94% | 1419/5465 |
| 近一月 | -1.13% | 1043/5421 |
| 近一季 | -3.28% | 1595/5231 |
| 近半年 | -4.84% | 2948/4920 |
| 近一年 | 4.90% | 1785/4394 |
| 近两年 | 29.91% | 2283/2954 |
| 近三年 | 17.86% | 1566/2253 |
| 成立以来 | 59.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.18% 1614/4961 |
7.55% 2691/5312 |
- - |
- - |
| 2025 | 5.96% 2979/4813 |
-4.96% 3240/3635 |
1.07% 2477/4076 |
10.19% 3317/4524 |
0.11% 2206/4813 |
| 2024 | 15.51% 920/3463 |
4.86% 424/2808 |
2.02% 412/3014 |
8.58% 2739/3129 |
-0.56% 1464/3463 |
| 2023 | 1.37% 355/2656 |
12.34% 297/2280 |
-0.79% 418/2385 |
-4.78% 1219/2515 |
-4.48% 1053/2655 |
| 2022 | -14.93% 400/2207 |
-12.09% 570/1919 |
3.44% 1151/2016 |
-9.87% 324/2113 |
3.79% 641/2208 |
| 2021 | 15.79% 293/1822 |
-0.31% 349/1255 |
4.62% 864/1330 |
8.85% 152/1466 |
2.00% 727/1822 |
| 2020 | 14.73% 790/1250 |
-10.19% 765/1028 |
4.78% 900/1067 |
9.24% 662/1164 |
11.61% 532/1184 |
| 2019 | 5.47% 765/1092 |
12.00% 712/739 |
-7.07% 540/788 |
-1.34% 645/850 |
2.71% 860/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证央企ETF联接C VS. 长安沪深300非周期A(740101) |